Your question:
“What happened to the confidence that they could license the diagnostic test? Obviously, if they're looking to raise $25mm on objectively terrible terms, they don't expect significant funding from that in even the coming months. But since about November, they've spoken like that's imminent. That's exceptionally frustrating to me. It blows my mind that they can't find bridge funding if the diagnostic test is as valuable and easily-licensed as they've suggested.”
I spoke to Tony C a month ago about this as it appeared this could resolve the cash needed for the BLA and additional breathing room. I don’t quote my sources.
In my words let’s say it is not as simple and valuable as it may appear. Requires time and significant investment from the suitor. The bet is on Mono as the inflection point with 90% plus efficacy at 700mg dosage. Cancer play is big but much further out. All the more logic behind raising $ regardless of terms right now to get Combo BLA Filed as Mono is the key.
Pestell’s Cancer story is attracting the investment $. HIV story was out of gas going back to the same investors.
Pestell and the TNBC is the trophy magnet but let’s face it Mono can be a revenue generator with Combo approval as a label expansion almost immediately. That is the pressure the BP HIV players are going to need to feel for a deal to occur. Cancer play has added euphoria type numbers to Leronlimab. It may be real but we are a ways out for that to materialize.
I for one would jump at $10 per share this year. I’m not getting any younger and there are possibly millions of patients that need the benefits of Leronlimab. Let’s hand it off to deep pockets and expedite the process.
As for the private raise I believe it’s min. 250k.
AIMHO.
News 
Market Data 
Discover 
